ArticleInternational journal of clinical and experimental medicine2015
Visfatin expression and genetic polymorphism in patients with traumatic brain injury.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Relationship of visfatin with obesity and osteoporosis in patients with inflammatory bowel disease: a narrative review.Frontiers in immunology · 2025Review
- Role of visfatin in obesity-induced insulin resistance.World journal of clinical cases · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo discover the expression of visfatin and its genetic mutation and clinical significance in patients with traumatic brain injury.
methods99 cases of traumatic brain injury patients admitted to Chongqing Emergency Medical Center from June 2013 to December 2014. There were 56 male and 43 female with an average age of 45.2 years. Through diagnosis, the 99 patient's conditions were all relatively in accordance with traumatic brain injury standard; meanwhile, the patients were divided into mild, moderate and severe traumatic brain injury according to GCS criteria when they admitted to clinics. 33 people were enrolled in each group. To highlight the results, 40 healthy people were enrolled in the control group with 25 males and 15 females. ELISA was used to detect serum visfatin level in 99 patients. Single base extension was used to detect visfatin gene promoter -1535C/T polymorphism.
resultsBy examination we found that visfatin gene -1535C > T locus had three genotypes: TT, TC and CC, respectively. By examination we obtained that genotype distribution and allele frequency showed no significance between the experimental group and the control group (P > 0.05). Through analysis we can get that serum visfatin level in patients with traumatic brain injury was significantly higher than that in the control group. CC genotype are mostly patients with severe traumatic brain injury, and its serum visfatin level was higher than that with CT and TT genotype (all P < 0.05). CT and TT genotype carriers were most mild and moderate traumatic brain injury patients.
conclusionExpression of visfatin and its gene mutation in patients with traumatic brain injury were closely related to the severity of the disease.
Indexed as
Identifiers
26309659PMC4538163W2416982034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.